{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:01:35Z","timestamp":1779310895835,"version":"3.51.4"},"reference-count":245,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2023,3,4]]},"DOI":"10.1080\/13543776.2023.2206017","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T18:42:45Z","timestamp":1682534565000},"page":"211-245","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Novel therapeutic opportunities for <i>Toxoplasma gondii<\/i>, <i>Trichomonas vaginalis,<\/i> and <i>Giardia intestinalis<\/i> infections"],"prefix":"10.1080","volume":"33","author":[{"given":"Francesca","family":"Arrighi","sequence":"first","affiliation":[{"name":"Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Granese","sequence":"additional","affiliation":[{"name":"Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Chimenti","sequence":"additional","affiliation":[{"name":"Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5701-6925","authenticated-orcid":false,"given":"Paolo","family":"Guglielmi","sequence":"additional","affiliation":[{"name":"Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-micro-091014-104100"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1111\/j.1550-7408.2008.00345.x"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000270"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762009000200003"},{"issue":"1","key":"cit0005","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.sjbs.2020.11.007","volume":"28","author":"S Al Malki E","year":"2021","journal-title":"Saudi J Biol Sci"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2017.1316494"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01754"},{"key":"cit0008","first-page":"31","volume":"69","author":"Stani\u0107 \u017d","year":"2020","journal-title":"Veterinaria"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2009.02.004"},{"issue":"1","key":"cit0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00115-19","volume":"34","author":"Elsheikha HM","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1101\/688580"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-020-04445-z"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.64.3.607-623.2000"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4922(02)02240-7"},{"key":"cit0015","first-page":"1","volume":"8","author":"Wang ZD","year":"2017","journal-title":"Front Microbiol"},{"issue":"3","key":"cit0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pathogens9030234","volume":"9","author":"Cerutti A","year":"2020","journal-title":"Pathogens"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182012000765"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212375"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-animal-081720-111125"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piu077"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03648.x"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2014.00385"},{"issue":"3","key":"cit0023","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4103\/0974-777X.83536","volume":"3","author":"Furtado JM","year":"2011","journal-title":"J Glob Infect Dis"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.00389"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10112176"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.4.794-803.2004"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1078\/143446103322454095"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.15698\/mic2016.09.526"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1097\/01.olq.0000218869.52753.c7"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000134"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2018-053713"},{"key":"cit0032","unstructured":"Hooshyar H, Rostamkhani P, Arbabi M, et al. Giardia lamblia infection: review of current diagnostic strategies. n.d."},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10122422"},{"key":"cit0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fmicb.2020.618106","volume":"11","author":"Fekete E","year":"2021","journal-title":"Front Microbiol"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-51-13809"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-71-17074"},{"key":"cit0037","first-page":"483","volume":"3","author":"Eyles DE","year":"1953","journal-title":"Antibiot & Chemother"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM195712262572601"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.fawpar.2019.e00036"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-44-3-557"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-3860"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/C2012-1-00075-6"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-1-33"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.2.268"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.10.2049"},{"issue":"5","key":"cit0046","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1128\/AAC.36.5.1091","volume":"36","author":"Pfefferkorn ER","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.12.2571"},{"issue":"5","key":"cit0048","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1046\/j.1365-2958.2002.02825.x","volume":"43","author":"Camps M","year":"2002","journal-title":"Mol Microbiol"},{"key":"cit0049","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jac\/22.Supplement_B.87","volume":"22","author":"Chang HR","year":"1988","journal-title":"J Antimicrob Chemother"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S60973"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1007\/BF01963942"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2009.02.004"},{"key":"cit0053","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jac\/22.Supplement_B.193","volume":"22","author":"Couvreur J","year":"1988","journal-title":"J Antimicrob Chemother"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2022.2080656"},{"issue":"6","key":"cit0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11908-015-0484-7","volume":"17","author":"Kissinger P","year":"2015","journal-title":"Curr Infect Dis Rep"},{"issue":"14","key":"cit0056","first-page":"665","volume":"86","author":"Robinson SC","year":"1962","journal-title":"Can Med Assoc J"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2021.01.002"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00910"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.03.001"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112650"},{"key":"cit0061","unstructured":"Central South University. Chalcone derivative, preparation method thereof and application thereof in toxoplasma gondii resistance. CN110963932A. 2019."},{"key":"cit0062","unstructured":"Shanghai Veterinary Research Institute (SHVRI). Application of quinoxaline-1,4-dioxide compounds in Anti-Toxoplasma gondii infection. CN110269859A. 2019."},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2016.12.015"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110524"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22109"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2005.06.035"},{"key":"cit0067","unstructured":"Washington University, The Broad Institute, Inc., President and fellows of Harvard College. Treatment of infections of Toxoplasma gondii and closely related parasites. WO2020061167A1. 2019."},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.11.4037-4044.2002"},{"key":"cit0069","unstructured":"Application filed by Washington University, the Broad Institute, Inc. compounds and methods for the treatment of Toxoplasma gondii infection. WO2019232417A1. 2019."},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxy004"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-385157-4.00182-2"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.3390\/ph3040795"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2019.0076"},{"key":"cit0074","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fimmu.2020.00011","volume":"11","author":"Walter MR","year":"2020","journal-title":"Front Immunol"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197596"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1007\/s43032-022-01110-x"},{"key":"cit0077","doi-asserted-by":"crossref","unstructured":"Pfefferkorn ER Interferon y blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan (tryptophan\/kynurenine\/N-formylkynurenine). 81. 1984.","DOI":"10.1073\/pnas.81.3.908"},{"issue":"4851","key":"cit0078","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.3128869","volume":"240","author":"Suzuki Y","year":"1979","journal-title":"Science"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.05543-11"},{"issue":"2","key":"cit0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/metabo11020061","volume":"11","author":"Krishnan A","year":"2021","journal-title":"Metabolites"},{"key":"cit0081","unstructured":"University of Chicago Northwestern University. Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria. US10632088B2. 2020."},{"issue":"24","key":"cit0082","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1021\/ja00024a042","volume":"113","author":"Burke JR","year":"1991","journal-title":"J Am Chem Soc"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2016.12.024"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1021\/jm201231w"},{"issue":"7","key":"cit0085","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/0024-3205(77)90505-7","volume":"20","author":"Matsui Y","year":"1977","journal-title":"Life Sci"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01192"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00760"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy664"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00419"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2017.12.006"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.00025"},{"key":"cit0092","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejmech.2019.111711","volume":"183","author":"Deng Y","year":"2019","journal-title":"Eur J Med Chem"},{"key":"cit0093","unstructured":"University of Washington. Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases. CA2974702A1. 2019."},{"key":"cit0094","unstructured":"University of Washington Center for Commercialization. Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US11247972B2. 2020."},{"key":"cit0095","unstructured":"University of Washington Center for Commercialization. 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C parvum. US2016090362A1. 2016."},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1007\/7355_2021_142"},{"issue":"23","key":"cit0097","doi-asserted-by":"crossref","first-page":"13143","DOI":"10.1073\/pnas.93.23.13143","volume":"93","author":"Darkin-Rattray SJ","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"cit0098","unstructured":"Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier I, Institut de Recherche pour le Developpement IRD. New compounds for the treatment and\/or prevention of parasitic diseases and method of production of thereof. US2019040004A1. 2018."},{"issue":"9","key":"cit0099","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.41.9.1849","volume":"41","author":"McFadden DC","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"cit0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0920-9964(02)00357-2","volume":"62","author":"Jones-Brando L","year":"2003","journal-title":"Schizophr Res"},{"key":"cit0101","unstructured":"Obihiro University of Agriculture and Veterinary Medicine NUC. Histone deacetylase inhibitor having antiprotozoal action. JP2019038749A. 2017."},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2020.10.004"},{"key":"cit0103","unstructured":"Council of Scientific and Industrial Research CSIR. Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity. US10550135B2. 2017."},{"key":"cit0104","unstructured":"Council of Scientific and Industrial Research CSIR. Silicon based cyclic compounds and pharmaceutical compositions for treating malaria and toxoplasmosis. US10562922B2. 2017."},{"key":"cit0105","unstructured":"Shandong University. Novel thiazole derivatives, and preparation method and application thereof. CN106632133A. 2016."},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.05.020"},{"key":"cit0107","unstructured":"Chongqing Academy of Animal Sciences. Febrifugine derivatives and preparation method and application thereof. CN111100079A. 2019."},{"key":"cit0108","first-page":"110","volume":"110","author":"Wang G","year":"2023","journal-title":"Phytomedicine"},{"key":"cit0109","unstructured":"Affiliated Hospital Of Inner Mongolia University For Nationalities. Arctiin metaclass compound and its preparation method and application. CN108863994A. 2018."},{"key":"cit0110","unstructured":"Affiliated Hospital Of Inner Mongolia University For Nationalities. Compound, preparation method and purposes based on arctigenin. CN108997268A. 2018."},{"key":"cit0111","unstructured":"Affiliated Hospital Of Inner Mongolia University For Nationalities. Arctiin metaclass compound, preparation method and purposes. CN109053701A. 2018."},{"key":"cit0112","unstructured":"Affiliated Hospital Of Inner Mongolia University For Nationalities. Compound and its preparation method and application based on arctigenin. CN108640891A. 2018."},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1080\/21691401.2018.1489267"},{"key":"cit0114","unstructured":"Obihiro University of Agriculture and Veterinary Medicine NUC. Anti-toxoplasma agent and medicine containing the same. JP2018177663A. 2017."},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1468"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.168"},{"key":"cit0117","first-page":"12","volume":"12","author":"Hamie M","year":"2021","journal-title":"Front Immunol"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00387"},{"key":"cit0119","unstructured":"Shandong University. Application of the tipranavir in the drug that preparation inhibits toxoplasma growth. CN110302199A. 2019."},{"key":"cit0120","unstructured":"Shandong University. Application of tenofovir disoproxil fumarate in the preparation of drugs for inhibiting the growth of Toxoplasma gondii. CN110302206A. 2019."},{"key":"cit0121","unstructured":"Shandong University. Application of Elvitegravir in the preparation of drugs for inhibiting the growth of Toxoplasma gondii, CN110302200A_Original_document_20221117164439, n.d."},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.2174\/1568026619666190712204603"},{"issue":"2","key":"cit0123","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/2229-5070.190817","volume":"6","author":"Basavaraju A","year":"2016","journal-title":"Trop Parasitol"},{"key":"cit0124","unstructured":"Wenzhou Medical University. A kind of screening of micromolecular inhibitor that can suppress infection of Toxoplasma gondii propagation and application process. CN107884587A. 2017."},{"key":"cit0125","unstructured":"Wenzhou Medical University. Application of a small molecule inhibitor for preparing Toxoplasma gondii proliferation. CN108057037A. 2017."},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-020-04094-2"},{"key":"cit0127","unstructured":"Dongyang Peoples Hospital. Application of a small molecule inhibitor capable of inhibiting the proliferation of Toxoplasma gondii. CN114788830A. 2022."},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237411"},{"key":"cit0129","unstructured":"Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of aminothiazole compounds in preparation of medicine for treating Toxoplasma gondii infection diseases. CN113509468A. 2021."},{"key":"cit0130","unstructured":"Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of quinoline compound broxaldine in inhibiting activity of Toxoplasma gondii infection diseases. CN113069452A. 2021."},{"key":"cit0131","unstructured":"Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of hycanthone in preparation of medicine for treating Toxoplasma gondii infection diseases. CN113398118A. 2021."},{"key":"cit0132","unstructured":"Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of niclosamide in treatment of Toxoplasmosis. CN110478356A. 2019."},{"key":"cit0133","unstructured":"Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of myrislignan in treating Toxoplasmosis. CN110876739A. 2019."},{"key":"cit0134","unstructured":"Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of octyl gallate in preparation of medicine for preventing and\/or treating Toxoplasmosis. CN114042060A. 2021."},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2013.08.048"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.08.023"},{"key":"cit0137","unstructured":"Celgene corp; Zoetis llc. Heterocyclic compounds and their use for treatment of helminthic infections and diseases. WO2020219871A1. 2020."},{"issue":"7903","key":"cit0138","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0140-6736(75)91334-3","volume":"305","author":"Gangadhar Sharma CS","year":"1975","journal-title":"Lancet"},{"issue":"3","key":"cit0139","first-page":"118","volume":"17","author":"Pashov D","year":"1980","journal-title":"Vet Med Nauki"},{"issue":"6","key":"cit0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1371\/journal.pone.0178203","volume":"12","author":"Murata Y","year":"2017","journal-title":"PLoS ONE"},{"key":"cit0141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2018.12.004"},{"issue":"4","key":"cit0142","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2165\/00003495-198632040-00004","volume":"32","author":"Katz M","year":"1986","journal-title":"Drugs"},{"key":"cit0143","unstructured":"The Catholic University Industry-University Cooperation Foundation. Composition for preventing and treating Toxoplasma gondii infection comprising dacomitinib. KR101508610B1. 2015."},{"key":"cit0144","unstructured":"The Catholic University Industry-University Cooperation Foundation. Composition for preventing and treating Toxoplasma gondii infection comprising afatinib. KR101508611B1. 2015."},{"key":"cit0145","unstructured":"The Catholic University Industry-University Cooperation Foundation. Composition for preventing and treating Toxoplasma gondii infection comprising crizotinib. KR101538385B1. 2015."},{"key":"cit0146","unstructured":"The Catholic University Industry-University Cooperation Foundation. Composition for preventing and treating Toxoplasma gondii infection comprising pelitinib. KR20150027404A. 2015."},{"key":"cit0147","unstructured":"The Catholic University Industry-University Cooperation Foundation. Pharmaceutical composition for prevention or treatment of toxoplasmosis, comprising anti-non-small cell lung cancer agent as active ingredient. WO2015030504A1. 2015."},{"key":"cit0148","doi-asserted-by":"publisher","DOI":"10.3347\/kjp.2017.55.5.491"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-021-01994-9"},{"key":"cit0150","unstructured":"The Catholic University Industry-University Cooperation Foundation. c-Met pharmaceutical composition comprising c-Met kinase inhibitor as active ingredient for preventing or treating Toxoplasma gondii. KR102304573. 2020."},{"issue":"656","key":"cit0151","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn3231","volume":"14","author":"Swale C","year":"2022","journal-title":"Sci Trans Med"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01310-7"},{"key":"cit0153","unstructured":"The Catholic University Industry-University Cooperation Foundation. VEGFR2 pharmaceutical composition comprising VEGFR2 inhibitor as active ingredient for preventing or treating Toxoplasma gondii. KR102301217B1. 2020."},{"key":"cit0154","unstructured":"Obihiro University of Agriculture and Veterinary Medicine NUC. Anti-Toxoplasma gondii agent. JP2019077633A. 2017."},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-017-5698-1"},{"key":"cit0156","unstructured":"Obihiro University of Agriculture and Veterinary Medicine NUC. Anti-Toxoplasma agent. JP2018035079A. 2016."},{"key":"cit0157","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2013.743995"},{"key":"cit0158","doi-asserted-by":"publisher","DOI":"10.3390\/nu14030490"},{"key":"cit0159","doi-asserted-by":"publisher","DOI":"10.1039\/C9NP00049F"},{"key":"cit0160","unstructured":"Wuhan Polytechnic University. Application of parthenolide in preparation of anti-Toxoplasma gondii. drugs CN110179789A. 2019."},{"key":"cit0161","unstructured":"Nantong University. New application of IFN-lambda in Toxoplasma gondii infection. CN111494610A. 2020."},{"key":"cit0162","unstructured":"Nantong University. New use of IFN-lambda 3 in Toxoplasma gondii infection. CN111407883A. 2020."},{"key":"cit0163","unstructured":"Nantong University. New application of IFN-lambda 2 in Toxoplasma gondii infection. CN111494609A. 2020."},{"key":"cit0164","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2013.0062"},{"key":"cit0165","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.470"},{"key":"cit0166","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2022.11283"},{"key":"cit0167","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.07.017"},{"key":"cit0168","doi-asserted-by":"publisher","DOI":"10.1016\/j.xfss.2022.09.003"},{"key":"cit0169","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod.108.073353"},{"key":"cit0170","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-022-05455-9"},{"key":"cit0171","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03279-14"},{"issue":"8","key":"cit0172","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/1535370218772802","volume":"243","author":"Shen H","year":"2018","journal-title":"Exp Biol Med"},{"key":"cit0173","unstructured":"Central South University. Application of polypeptide Lycosin-I in preparing anti-inflammatory and Toxoplasma gondii-preventing drug. CN107496904A. 2017."},{"key":"cit0174","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2019.01.009"},{"key":"cit0175","unstructured":"Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Use of sabinene in preparing medicine for killing or preventing parasitic diseases. CN112402401A. 2020."},{"key":"cit0176","unstructured":"Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of naringenin and naringenin composition in preparation of medicine for treating or preventing toxoplasmosis. CN112843046A. 2021."},{"key":"cit0177","unstructured":"Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Method for treating toxoplasmosis by using isoflavonoid compound glabridin. CN113197888A. 2021."},{"key":"cit0178","unstructured":"Ningbo University. Application of licarin-B and composition thereof in preparation of medicine for treating or preventing toxoplasmosis. CN113230248A. 2021."},{"key":"cit0179","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.684393"},{"key":"cit0180","unstructured":"Yanbian University. Application of coixol in preparation of medicine for preventing and treating toxoplasmosis. CN114522161A. 2021."},{"key":"cit0181","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110031"},{"key":"cit0182","unstructured":"Guangxi University. Application of piceatannol in resisting toxoplasma infection. CN114917209A. 2022."},{"key":"cit0183","unstructured":"Shi D, Zhang X, Song X, et al. The Anti-Toxoplasma activity of the plant natural phenolic compound piceatannol. n.d."},{"key":"cit0184","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02152"},{"key":"cit0185","unstructured":"Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of traditional Chinese medicine monomer licochalcone a in treating toxoplasmosis. CN110507639A. 2019."},{"key":"cit0186","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2018.02.006"},{"issue":"12","key":"cit0187","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13543776.2020.1853101","volume":"30","author":"Guglielmi P","year":"2020","journal-title":"Expert Opin Ther Pat"},{"key":"cit0188","doi-asserted-by":"publisher","DOI":"10.1016\/S2221-1691(13)60075-1"},{"key":"cit0189","unstructured":"Ijaz H, Tulain UR, Qureshi J, et al. Nigella sativa (Prophetic medicine): a review. 2017;30."},{"key":"cit0190","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-015-4759-6"},{"key":"cit0191","first-page":"165","volume":"4","author":"Rayan HZ","year":"2011","journal-title":"PUJ"},{"key":"cit0192","unstructured":"Baris D. The anti-cancerous, antiparasite (Toxoplasma gondii (protozoon) and antimicrobial effect and dosage of nigella (Nigella sativa) extract. WO2016108775A1. 2016."},{"key":"cit0193","unstructured":"Baris D. Anti-cancerous, antiparasite (Toxoplasma gondii (protozon) and antimicrobial effect and dosage of ginger (Zingiber officinale). extractUS20170348374A1. 2017."},{"key":"cit0194","unstructured":"Wonkwang University Industry-University Cooperation Foundation. A composition comprising the extract of Suaeda maritima showing anti-toxoplasma activity. KR20150073740A. 2015."},{"key":"cit0195","unstructured":"Wonkwang University Industry-University Cooperation Foundation. A composition comprising the extract of Plantago asiatica showing anti-toxoplasma activity. KR101710588B1. 2015."},{"key":"cit0196","doi-asserted-by":"publisher","DOI":"10.1016\/j.phytochem.2019.112231"},{"key":"cit0197","unstructured":"Yanbian University. Daphne giraldii extract submicron emulsion preparation for treating toxoplasmosis and preparation method thereof. CN111671825A. 2020."},{"key":"cit0198","unstructured":"Rongcheng Fei Chuang Technology Co Ltd. Traditional Chinese medicine composition for killing Toxoplasma gondii. CN107823518A. 2017."},{"key":"cit0199","unstructured":"Inst Politecnico Nacional. Use of novel trichomonacidal molecules. MX2016013109A. 2016."},{"key":"cit0200","unstructured":"Inst Politecnico Nacional. Use of trichomonacidal molecules. MX2016013111A. 2016."},{"key":"cit0201","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbiopara.2021.111413"},{"key":"cit0202","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-374984-0.00048-6"},{"key":"cit0203","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201800084"},{"key":"cit0204","unstructured":"Univ Madrid Complutense; Consejo Superior De Inventigaciones Cientificas Csic; Centro De Bioactivos Quim. Amines derived from 2-benzyl-5-nitroindazole with antiprotozoal properties against trypanosoma, leishmania and trichomonas. WO2019077174A1. 2018."},{"issue":"3929","key":"cit0205","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.168.3929.373","volume":"168","author":"Kantor S","year":"1979","journal-title":"Science"},{"key":"cit0206","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2015.11.005"},{"key":"cit0207","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01797"},{"key":"cit0208","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.3.329-341.2002"},{"key":"cit0209","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202200341"},{"key":"cit0210","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183457"},{"key":"cit0211","unstructured":"Pty Ltd N. Methods for treating protozoan infections. US10392363B2. 2019."},{"issue":"4","key":"cit0212","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2174\/1570180816666190618115854","volume":"17","author":"Barbosa-Cabrera E","year":"2019","journal-title":"Lett Drug Des Discov"},{"key":"cit0213","unstructured":"Inst Politecnico Nacional. Use of quinoxaline 1,4-di-N-oxide ester derivatives for the treatment of giardiasis as anti-giardia-lamblia agents. MX2017012677A. 2017."},{"key":"cit0214","unstructured":"Jilin University. Giardia chaperonin J inhibitor KNK437 and medical application thereof. CN112546045A. 2021."},{"key":"cit0215","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S49629"},{"issue":"9","key":"cit0216","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1128\/AAC.38.9.2204","volume":"38","author":"Niwano Y","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0217","unstructured":"Pola Pharma Inc., Nihon Nohyaku Co., Ltd. Anti-tritrichomonas agent. WO2017168476A1. 2016."},{"key":"cit0218","first-page":"57","volume":"57","author":"Matos APS","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"key":"cit0219","unstructured":"Cheng Y, Honggang Z, Tao S. Application of paromomycin to preparation of medicine for treating Trichomonas vaginitis. CN105726552A. 2016."},{"key":"cit0220","unstructured":"Guadalajara U. Use of terfenadine for the treatment of parasitic diseases. MX2019003675A. 2019."},{"key":"cit0221","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.7717\/peerj.6430","volume":"7","author":"Palomo-Ligas L","year":"2019","journal-title":"Peer J"},{"key":"cit0222","unstructured":"King Abdulaziz University. Composition containing essential oils and plant extracts for treating vaginal infection and inflammation. US10154958B1. 2017."},{"key":"cit0223","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110405"},{"issue":"2","key":"cit0224","first-page":"10","volume":"10","author":"Batiha GES","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"cit0225","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13071-019-3520-x","volume":"12","author":"Beshbishy AM","year":"2019","journal-title":"Parasites Vectors"},{"key":"cit0226","unstructured":"Autonoma De Nuevo Leon U. Secondary fraction of the acetonic Syzygium aromaticum extract and its use as an amebicide and tricomonicide agent. MX2015008518A. 2015."},{"key":"cit0227","unstructured":"Karuppannan K, Priyadharshini SD, Kokila K, et al. Phytopharmacological properties of Albizia species: a review. 2013."},{"key":"cit0228","doi-asserted-by":"publisher","DOI":"10.1016\/j.ibiod.2010.11.011"},{"key":"cit0229","first-page":"2019","volume":"2019","author":"Chang JS","year":"2019","journal-title":"Evid Compl Alternat Med"},{"key":"cit0230","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.116002"},{"key":"cit0231","unstructured":"Biospectrum Inc. An antibacterial composition containing the extracts of silk tree bark and the feminine cleanser composition comprising the same. KR20190092038A. 2019."},{"key":"cit0232","unstructured":"Biospectrum Inc. A antibacterial composition containing the defatted Camellia\u2019s seed extract and the feminine cleanser composition comprising the same. KR102172448B1. 2018."},{"key":"cit0233","unstructured":"Qingdao Huangdao Hospital of Traditional Chinese Medicine. Chinese medicament for treating trichomonas vaginitis and preparation method. CN104740113A. 2015."},{"key":"cit0234","unstructured":"Zibo Qidingli Patent Information Consulting Co Ltd. Traditional Chinese medicine suppository for treating trichomonas vaginitis. CN105106763A. 2015."},{"key":"cit0235","unstructured":"Jiangsu Kangba Special Biological Engineering Co Ltd. Preparation method for pure Chinese herbal medicine antibacterial lotion special for gynecology. CN108434378A. 2018."},{"key":"cit0236","unstructured":"Peng C. Traditional Chinese medicine for treating trichomoniasis intestinalis. CN106620112A. 2016."},{"key":"cit0237","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2014.04.005"},{"key":"cit0238","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2571(01)00034-6"},{"key":"cit0239","unstructured":"Ct De Investigaci\u00f3n Y De Estudios Avanzados Del I P N. Trichosystatin-2(TC-2) a cysteine proteinase inhibitor TvCP39 of Trichomonas vaginalis. MX2014010400A. 2016."},{"issue":"11","key":"cit0240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4103\/0973-7847.95855","volume":"6","author":"Cock I","year":"2012","journal-title":"Pharmacogn Rev"},{"issue":"8","key":"cit0241","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/foods8080281","volume":"8","author":"Akter S","year":"2019","journal-title":"Foods"},{"key":"cit0242","unstructured":"Gunaguddya Pty Ltd. Treatment or prevention of giardiasis with a biologically active extract from terminalia ferdinandiana fruit. WO2017063017A1. 2017."},{"key":"cit0243","unstructured":"Rising Phoenix Industries Pty Ltd. Terminalia ferdinandiana extract and products containing extract of terminalia ferdinandiana for antimicrobial or antibacterial applications. CA3062204A1. 2018."},{"key":"cit0244","unstructured":"Agronomique Inst Nat Rech; Museum Nat Dhistoire Naturelle; Ecole Nat Veterinaire Dalfort. Compositions for the inhibition of Giardia lamblia. US10328132B2. 2019."},{"key":"cit0245","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01453"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2023.2206017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T14:14:32Z","timestamp":1683209672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2023.2206017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,4]]},"references-count":245,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,4]]}},"alternative-id":["10.1080\/13543776.2023.2206017"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2023.2206017","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}